Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ERAS-601 + cetuximab
- Development stage
- Phase 1
- Lead developer
- Erasca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
ERAS-601 + cetuximab is a combination therapy for advanced or metastatic solid tumors, currently in clinical trials for chordoma and other cancers. ERAS-601 is a potent, selective, and orally bioavailable small molecule allosteric inhibitor of SHP2—a non-receptor protein tyrosine phosphatase encoded by PTPN11—disrupting receptor tyrosine kinase signaling to the RAS/MAPK pathway[2][4][1]. Cetuximab is a monoclonal antibody targeting epidermal growth factor receptor (EGFR), blocking its activity and thereby inhibiting cell proliferation and survival signals in tumors[1][4]. The combination leverages dual inhibition of SHP2 and EGFR, showing promising anti-tumor activity in preclinical and early clinical studies of chordoma, head and neck squamous cell carcinoma (HNSCC), and RAS/RAF wild-type colorectal cancer[4][1].
- Other names
- ERAS-601 + cetuximab
02
Targets
EGFR (Epidermal growth factor receptor)PTPN11 (Tyrosine-protein phosphatase non-receptor type 11)
Beyond the preview
Go deeper on ERAS-601 + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ERAS-601 + cetuximab.